OBJECTIVES

: Determine if the inclusion in the prescription behavior of the medications from the group of sodium-glucose cotransporter inhibitors type 2 (SGLT2) as monotherapy to the Health benefits plan (PBS) due to Resolution 5857 of 2018 of Colombia will change the prescription behavior

METHODS

: A database with prescriptions of SGLT2 medications was taken from two Health Maintenance Organization (HMO) in Bogota, Colombia for the 2017 - 2019 period. We made an interrupted time series analysis for comparing the medicines of monotherapy group included in PBS against a control group (SGLT2/Metformin) not included in the policy. Statistical significance tests were applied in the monthly prescription rates to explain the behavior during the study period and a moving average auto-regression model was done. The database was provided by the integral pharmaceutical manager based on the dispensations generated for the HMO

RESULTS

: From the database provided 8,762 patients with prescription medications from the SGLT2 group were identified. The average monthly prescription rate prior to the inclusion of SGLT2 monotherapy to PBS was 4.3 and 1.8 for the HMO´s. After 32.2 and 10.3 respectively. No significant differences were found with the control group before the policy measure. However, the subsequent variation coefficient for SGLT2 was 4.64 (CI 4.15 - 5.11 95%) for HMO 1 and 1.10 (CI 0.98 - 1.22 95%) for HMO 2 versus the control group of 0.29 (CI 0.21 - 0.37 95% ) for HMO1 and 0.14 (0.11 - 0.16 95%) for HMO 2.

CONCLUSIONS

: The results suggest that implementation of the policy has a positive impact on users, concerning the access of technologies that were not previously covered in PBS. However, historical behavior does not allow to estimate the future impact of the policy.